All Updates

All Updates

icon
Filter
Partnerships
SimBioSys and Mayo Clinic collaborate to develop solutions for breast cancer
AI Drug Discovery
Jan 2, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 2, 2024

SimBioSys and Mayo Clinic collaborate to develop solutions for breast cancer

Partnerships

  • Illinois-based AI drug discovery company SimBioSys has partnered with Mayo Clinic to develop cloud-based clinical software solutions for breast cancer patients. The terms and financial details of the agreement have not been disclosed.

  • The collaboration will leverage Mayo Clinic's data to create cloud-powered clinically inclined software tools to facilitate decision-making for early-stage breast cancer patients, including personalized surgical planning and treatment. SimBioSys is also developing a cloud-based platform, TumorSight, currently under FDA evaluation, capable of constructing a 3D digital model from standard patient imaging to assist in surgical planning.

  • Founded in 2016, SimBioSys focuses on developing precision medicine in cancer care using its software platform that simulates the biochemical interactions within a patient’s tumor to identify the best treatment for the patient. The platform offers metabolic modeling, spatial characterization, drug delivery modeling, and novel biomarkers.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.